422 related articles for article (PubMed ID: 15706485)
1. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.
Roelfsema JH; White SJ; Ariyürek Y; Bartholdi D; Niedrist D; Papadia F; Bacino CA; den Dunnen JT; van Ommen GJ; Breuning MH; Hennekam RC; Peters DJ
Am J Hum Genet; 2005 Apr; 76(4):572-80. PubMed ID: 15706485
[TBL] [Abstract][Full Text] [Related]
2. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
Korzus E
Adv Exp Med Biol; 2017; 978():39-62. PubMed ID: 28523540
[TBL] [Abstract][Full Text] [Related]
3. Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300.
Bartholdi D; Roelfsema JH; Papadia F; Breuning MH; Niedrist D; Hennekam RC; Schinzel A; Peters DJ
J Med Genet; 2007 May; 44(5):327-33. PubMed ID: 17220215
[TBL] [Abstract][Full Text] [Related]
4. Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations.
Fergelot P; Van Belzen M; Van Gils J; Afenjar A; Armour CM; Arveiler B; Beets L; Burglen L; Busa T; Collet M; Deforges J; de Vries BB; Dominguez Garrido E; Dorison N; Dupont J; Francannet C; Garciá-Minaúr S; Gabau Vila E; Gebre-Medhin S; Gener Querol B; Geneviève D; Gérard M; Gervasini CG; Goldenberg A; Josifova D; Lachlan K; Maas S; Maranda B; Moilanen JS; Nordgren A; Parent P; Rankin J; Reardon W; Rio M; Roume J; Shaw A; Smigiel R; Sojo A; Solomon B; Stembalska A; Stumpel C; Suarez F; Terhal P; Thomas S; Touraine R; Verloes A; Vincent-Delorme C; Wincent J; Peters DJ; Bartsch O; Larizza L; Lacombe D; Hennekam RC
Am J Med Genet A; 2016 Dec; 170(12):3069-3082. PubMed ID: 27648933
[TBL] [Abstract][Full Text] [Related]
5. DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS.
Bartsch O; Schmidt S; Richter M; Morlot S; Seemanová E; Wiebe G; Rasi S
Hum Genet; 2005 Sep; 117(5):485-93. PubMed ID: 16021471
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular characterization of Rubinstein-Taybi syndrome patients carrying distinct novel mutations of the EP300 gene.
Negri G; Milani D; Colapietro P; Forzano F; Della Monica M; Rusconi D; Consonni L; Caffi LG; Finelli P; Scarano G; Magnani C; Selicorni A; Spena S; Larizza L; Gervasini C
Clin Genet; 2015 Feb; 87(2):148-54. PubMed ID: 24476420
[TBL] [Abstract][Full Text] [Related]
7. Mutations in CREBBP and EP300 genes affect DNA repair of oxidative damage in Rubinstein-Taybi syndrome cells.
Dutto I; Scalera C; Tillhon M; Ticli G; Passaniti G; Cazzalini O; Savio M; Stivala LA; Gervasini C; Larizza L; Prosperi E
Carcinogenesis; 2020 May; 41(3):257-266. PubMed ID: 31504229
[TBL] [Abstract][Full Text] [Related]
8. Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum.
López M; García-Oguiza A; Armstrong J; García-Cobaleda I; García-Miñaur S; Santos-Simarro F; Seidel V; Domínguez-Garrido E
BMC Med Genet; 2018 Mar; 19(1):36. PubMed ID: 29506490
[TBL] [Abstract][Full Text] [Related]
9. From Whole Gene Deletion to Point Mutations of EP300-Positive Rubinstein-Taybi Patients: New Insights into the Mutational Spectrum and Peculiar Clinical Hallmarks.
Negri G; Magini P; Milani D; Colapietro P; Rusconi D; Scarano E; Bonati MT; Priolo M; Crippa M; Mazzanti L; Wischmeijer A; Tamburrino F; Pippucci T; Finelli P; Larizza L; Gervasini C
Hum Mutat; 2016 Feb; 37(2):175-83. PubMed ID: 26486927
[TBL] [Abstract][Full Text] [Related]
10. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome.
Murata T; Kurokawa R; Krones A; Tatsumi K; Ishii M; Taki T; Masuno M; Ohashi H; Yanagisawa M; Rosenfeld MG; Glass CK; Hayashi Y
Hum Mol Genet; 2001 May; 10(10):1071-6. PubMed ID: 11331617
[TBL] [Abstract][Full Text] [Related]
11. Genetic and clinical heterogeneity in Korean patients with Rubinstein-Taybi syndrome.
Choi N; Kim HY; Lim BC; Chae JH; Kim SY; Ko JM
Mol Genet Genomic Med; 2021 Oct; 9(10):e1791. PubMed ID: 34427995
[TBL] [Abstract][Full Text] [Related]
12. Rubinstein-Taybi Syndrome: spectrum of CREBBP mutations in Italian patients.
Bentivegna A; Milani D; Gervasini C; Castronovo P; Mottadelli F; Manzini S; Colapietro P; Giordano L; Atzeri F; Divizia MT; Uzielli ML; Neri G; Bedeschi MF; Faravelli F; Selicorni A; Larizza L
BMC Med Genet; 2006 Oct; 7():77. PubMed ID: 17052327
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations.
Petrij F; Dauwerse HG; Blough RI; Giles RH; van der Smagt JJ; Wallerstein R; Maaswinkel-Mooy PD; van Karnebeek CD; van Ommen GJ; van Haeringen A; Rubinstein JH; Saal HM; Hennekam RC; Peters DJ; Breuning MH
J Med Genet; 2000 Mar; 37(3):168-76. PubMed ID: 10699051
[TBL] [Abstract][Full Text] [Related]
14. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP.
Petrij F; Giles RH; Dauwerse HG; Saris JJ; Hennekam RC; Masuno M; Tommerup N; van Ommen GJ; Goodman RH; Peters DJ
Nature; 1995 Jul; 376(6538):348-51. PubMed ID: 7630403
[TBL] [Abstract][Full Text] [Related]
15. Case report: a Chinese girl like atypical Rubinstein-Taybi syndrome caused by a novel heterozygous mutation of the EP300 gene.
Bai Z; Li G; Kong X
BMC Med Genomics; 2023 Feb; 16(1):24. PubMed ID: 36797748
[TBL] [Abstract][Full Text] [Related]
16. CBP-HSF2 structural and functional interplay in Rubinstein-Taybi neurodevelopmental disorder.
de Thonel A; Ahlskog JK; Daupin K; Dubreuil V; Berthelet J; Chaput C; Pires G; Leonetti C; Abane R; Barris LC; Leray I; Aalto AL; Naceri S; Cordonnier M; Benasolo C; Sanial M; Duchateau A; Vihervaara A; Puustinen MC; Miozzo F; Fergelot P; Lebigot É; Verloes A; Gressens P; Lacombe D; Gobbo J; Garrido C; Westerheide SD; David L; Petitjean M; Taboureau O; Rodrigues-Lima F; Passemard S; Sabéran-Djoneidi D; Nguyen L; Lancaster M; Sistonen L; Mezger V
Nat Commun; 2022 Nov; 13(1):7002. PubMed ID: 36385105
[TBL] [Abstract][Full Text] [Related]
17. Rubinstein-Taybi syndrome: clinical and molecular overview.
Roelfsema JH; Peters DJ
Expert Rev Mol Med; 2007 Aug; 9(23):1-16. PubMed ID: 17942008
[TBL] [Abstract][Full Text] [Related]
18. Chemical and genetic rescue of an ep300 knockdown model for Rubinstein Taybi Syndrome in zebrafish.
Babu A; Kamaraj M; Basu M; Mukherjee D; Kapoor S; Ranjan S; Swamy MM; Kaypee S; Scaria V; Kundu TK; Sachidanandan C
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1203-1215. PubMed ID: 29409755
[TBL] [Abstract][Full Text] [Related]
19. iPSC-derived neurons of CREBBP- and EP300-mutated Rubinstein-Taybi syndrome patients show morphological alterations and hypoexcitability.
Alari V; Russo S; Terragni B; Ajmone PF; Sironi A; Catusi I; Calzari L; Concolino D; Marotta R; Milani D; Giardino D; Mantegazza M; Gervasini C; Finelli P; Larizza L
Stem Cell Res; 2018 Jul; 30():130-140. PubMed ID: 29883886
[TBL] [Abstract][Full Text] [Related]
20. New insights into genetic variant spectrum and genotype-phenotype correlations of Rubinstein-Taybi syndrome in 39 CREBBP-positive patients.
Pérez-Grijalba V; García-Oguiza A; López M; Armstrong J; García-Miñaur S; Mesa-Latorre JM; O'Callaghan M; Pineda Marfa M; Ramos-Arroyo MA; Santos-Simarro F; Seidel V; Domínguez-Garrido E
Mol Genet Genomic Med; 2019 Nov; 7(11):e972. PubMed ID: 31566936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
